Related Experiment Video
Updated: Jun 26, 2026
Anterior High-Resolution Optical Coherence Tomography in the Diagnosis and Therapeutic Monitoring of Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
Topical mitomycin-C for treatment of partially-excised ocular surface squamous neoplasia
Firoozeh Rahimi1, Fateme Alipour, Hassan Ghazizadeh Hashemi
1Department of Ophthalmology, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Background:
This study was conducted to determine the treatment outcome of incompletely removed, histopathologically documented ocular surface squamous neoplasia with mitomycin-C.
Methods:
Through an interventional case series, 17 eyes of 17 patients presented with incompletely removed ocular surface squamous neoplasia were treated according to a protocol using two to three alternate seven-day courses of 0.04% mitomycin-C. Clinical recurrence was re-treated with the same protocol. All patients had weekly follow-up visits to the end of the treatment course, then biweekly visits for three months, and monthly visits, thereafter.
Results:
The mean+/-SD follow-up period was 30.76+/-4.4 (range: 24.5 - 41) months. Five patients (29.4%) experienced recurrence after the initial treatment; four of them responded to retreatment and were disease-free till the end of follow-up. Survival analysis with Kaplan-Meier method was performed. Taking into account four recurrences, the 41-month nonrecurrence rate was 70.6%. However, including four of five patients with recurrence who responded to retreatment, the final outcome in survival analysis was 94.1% nonrecurrence for 41 months of follow-up. All patients reported mild to moderate redness and irritation which were controlled with lubricants and mild corticosteroid eye drops. No serious ocular or systemic side effects were observed.
Conclusion:
Point zero four percent (0.04%) mitomycin-C drop used as two to three alternate seven-day courses seems to be a safe and effective treatment for ocular surface squamous neoplasia.
Insights
Topical mitomycin-C (0.04%) effectively treats ocular surface squamous neoplasia after incomplete removal. This treatment shows a high nonrecurrence rate with minimal side effects, offering a safe therapeutic option.
Area of Science:
- Ophthalmology
- Oncology
Background:
- Ocular surface squamous neoplasia (OSSN) requires effective treatment following incomplete surgical removal.
- Mitomycin-C is a chemotherapeutic agent with potential applications in treating OSSN.
Purpose of the Study:
- To evaluate the treatment outcomes of topical mitomycin-C for incompletely excised OSSN.
- To determine the safety and efficacy of this treatment protocol.
Main Methods:
- An interventional case series involving 17 patients with OSSN.
- Treatment with 0.04% mitomycin-C in alternate seven-day courses (2-3 courses).
- Recurrences were retreated with the same protocol, with extended follow-up.
Main Results:
- A 41-month nonrecurrence rate of 70.6% was observed initially.
- After retreatment, the final nonrecurrence rate reached 94.1%.
- Mild ocular irritation was reported, but no serious adverse events occurred.
Conclusions:
- Topical 0.04% mitomycin-C is a safe and effective treatment for OSSN.
- The protocol of alternate seven-day courses demonstrates favorable outcomes.
- Mitomycin-C offers a viable therapeutic option for residual OSSN.
